© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 VAP Prevention Bundle: Evidence Review for Oral Care and Subglottic.

Slides:



Advertisements
Similar presentations
Prevention of Ventilator Associated Pneumonia
Advertisements

PREVENTION OF CATHETER ASSOCIATED URINARY TRACT INFECTIONS (CAUTIs)
Eliminate Ventilator-Associated Pneumonia. What Is a Ventilator? A machine that supports breathing for those that have lost the ability to breathe Short.
Reducing Ventilator Associated Pneumonia in Adults Intensive Care Units Confidential: Quality Improvement Material.
Preventing catheter-associated urinary tract infections:
Key Elements Of Vent Bundle Terry Clemmer MD Vicki Spuhler RN MS.
OUR LADY OF LOURDES MEMORIAL HOSPITAL Binghamton, New York Reducing Complications From Ventilators in ICU: Ventilator Associated Pneumonia (VAP)
Linda R Greene Rochester General Hospital Rochester, NY
Ventilator Associated Pneumonia (VAP)
Ventilator Associated Pneumonia Best Practice Amy Shay, MS, CCRN, CNS Amy Shay, MS, CCRN, CNS.
Sean Berenholtz, MD MHS FCCM September 20, 2011 at 2ET/1 CT/12 MT/11 PT Ventilator Associated Pneumonia Prevention CLABSI Supplemental Call Series.
gain entrance to the lungs.”
Ventilator-Associated Pneumonia Prevention Michael J. Apostolakos, MD Associate Professor of Medicine Director, Adult Critical Care University of Rochester.
Ventilator-Associated Pneumonia. Introduction Definition 48 hours after intubation mechanically ventilated No clinical evidence of pneumonia prior to.
The Importance of Clinical Oral Care
Journal Club. Background to the paper Pneumonia is THE MOST COMMON nosocomial infection in ICU patients 12 to 18 cases per 1000 ventilator days Oropharyngeal.
Current Challenges in the ICU Prof Craig Williams Institute of Healthcare Associated Infection UWS.
Ventilator Associated Pneumonia Overview
CAUTI Prevention.
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 How Your Unit’s Policies and Protocols Compare to Other’s Kathleen.
Ventilator-Associated Pneumonia
Safer Healthcare Now! Ventilator Acquired Pneumonia Presented by Amanda Thompson, Safer Healthcare Now Facilitator April 12, 2007.
Preventing VAP - evidence for a care bundle. VAP Incidence ~ % ventilated patients 7-15 / 1000 ventilator days Atributable mortality of 0-50% Atributable.
TRACHEOSTOMY CARE AND EMERGENCIES. Indications for tracheostomy  Airway  Severe Facial Trauma,  Head and neck cancers / tumours  Acute Angioedema.
Reports: Daily Process, VAE, NHSN
Prevention of Nosocomial Infections
© 2009 On the CUSP: STOP BSI Evidence for Best Practices for Placement and Maintenance of Central Lines.
CLABSI: Working Toward Zero Trinity Regional Health System Infection Prevention and Control Presented by: Patricia Herath, BSN, RNC Infection Preventionist.
CSTS: The Cardiovascular Surgical Translational Study Senior Leadership of Quality and Safety Initiatives in Health Care Peter J. Pronovost, MD, PhD The.
Oral Care: State of the Science Vicki J. Spuhler RN MS Nurse Manager RICU LDS Hospital.
Oral Care for Patients at Risk for Ventilator-Associated Pneumonia Issued April 2010.
GENERAL TEMPLATE FOR A 48”X36” POSTER Name(s) of Author(s) 1 ; Name(s) of Author(s) 2 ; Name(s) of Author(s) 3 1. Name of Institution; 2. Name on Institution;
VAP Intervention Information
Clinical Uses and Ramifications of VAE Data
CUSP 4 MVP – VAP Improving Care for Mechanically Ventilated Patients Data Webinar 5 Defining the Early Mobility Measures ARMSTRONG INSTITUTE FOR PATIENT.
The Cardiac Surgery Translational Study (“CSTS”) The Quality And Safety Research Group Ventilator Associated Pneumonia Prevention Sean Berenholtz, MD MHS.
Improving ICU Care Through Teamwork
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 CUSP for VAP: Year in Review Sean Berenholtz, MD, MHS Kathleen Speck,
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 CUSP for VAP: EVAP Where are we going and How will we get there? Sean.
Part I BACKGROUND VENTILATOR ASSOCIATED PNEUMONIA.
CUSP for VAP: EVAP On Boarding Call #5: Evidence Review Sean Berenholtz M.D., MHS Nishi Rawat, M.D. September 18 th, :00 pm EST/ 11:00 am PST.
Pneumonia Dr. Abdul-Monim Batiha Assistant Professor Critical Care Nursing Philadelphia university.
ความหมาย As Pneumonia in patient who have been on mechanical ventilation for greater than 48 hrs.
Oral Care to Address Aspiration-risk Patients
CUSP 4 MVP – VAP Cohort 2 Data Webinar 2 How to Complete the Exposure Receipt Assessment | Preliminary Structural Assessment Data Reports Wednesday, February.
***Please note some slides have been removed since the webinar at the presenter’s request. CUSP for VAP Revisiting Your Action Plan: Using Reports to.
The Comprehensive Unit Based Safety Program (CUSP)
Spontaneous Awakening and Breathing Trials Brad Winters MD, PhD March 14, 2013.
CUSP 4 MVP-VAP: Subglottic Suction ETT Implementation
CUSP 4 MVP – VAP Improving Care for Mechanically Ventilated Patients Data Feedback: SubG ETT, Head of Bed Elevation and Delirium Assessment Utilization.
Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals 2014 Update Dr Neda Alijani.
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 Providing Feedback: Structural Assessment 2 Results & Exposure Receipt.
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 CSTS -VAP Prevention Data Collection Instructions Presented by Sean.
PREVENTION Kaplan University Capstone NU499 VENTILATOR – ASSOCIATED PNEUMONIA VAP PREVENTION at Sparks Regional Medical Center.
Ventilator-Associated Pneumonia (VAP) An Overview for RC Students Special thanks to: Donald Dumford Donald Dumford Beth Israel Deaconess Medical Center.
Ventilator Associated Pneumonia. Ventilator-associated pneumonia (VAP) is a form of hospital-associated pneumonia (HAP) which develops in mechanically.
Using Subglottic Endotracheal Tubes in Preventing Ventilator Assisted Pneumonia By: Nicole Durrance, Adriana Gomez, Esther Gonzalez, Marzette Solis BACKGROUND.
Ventilator-Associated Pneumonia
Purpose To decrease the number of Ventilator-Associated Pneumonias (VAP) at the SMBD-JGH.
Ventilator-associated pneumonia (VAP) prevention in Wales:
Subglottic Suctioning
Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.
A Quick Review: Preventing Ventilator-Associated Pneumonia (VAP)
Surveillance of Post-operative pneumonia
Rev: 17 January 2019.
Chapter 25 Respiratory Care Modalities
Ventilator-Associated Pneumonia
BIP Endotracheal Tube (ETT)
Presentation transcript:

© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 VAP Prevention Bundle: Evidence Review for Oral Care and Subglottic Suction ETTs Armstrong Institute for Patient Safety and Quality

Objectives To review the development of a VAP Prevention Bundle To review the evidence to support interventions in the VAP Prevention Bundle

Development of ‘VAP Prevention Bundle’ Funded by NIH/NHLBI –“A Multifaceted Intervention to Reduce Ventilator- Associated Pneumonia in the ICU” –Delphi process led by RAND researcher –Implement in statewide cohort of ICUs AHRQ funding –“ Comprehensive Unit-based Safety Program (CUSP) for Ventilator-Associated Pneumonia” –Pilot test in at least 2 hospitals in 2 states in anticipation of a national QI VAP Prevention project Armstrong Institute for Patient Safety and Quality 3

VAP Prevention Guidelines CDC Guidelines MMWR Recomm Rep. 2004;53:1-36 American Thoracic Society/ Infectious Diseases Society of America AJRCCM 2005;171(4): Canadian VAP Prevention Guidelines J Crit Care 2008;23(1): Society for Healthcare Epid of America ICHE 2008;29:S31-S40. Armstrong Institute for Patient Safety and Quality 4

Development of a New VAP Prevention Bundle: Delphi Process Interdisciplinary committee (n=155) –Focus on 65 guideline interventions Two web based rating cycles –First cycle, focus on importance effectiveness, strength and volume of clinical evidence, consistency of findings, and relevance –Second cycle, focus on importance, measurability and implementation feasibility Scale of 1 to 9, where 1 = low, 9 = essential > 90% response rates Armstrong Institute for Patient Safety and Quality 5

Process measures: Daily evaluation Use a semi-recumbent position ( ≥ 30 degrees). Make a daily assessment of readiness to wean. Use sedation protocol with sedation vacation and validated sedation scale (i.e. RASS) at least daily. Use chlorhexidine when performing oral care. Use subglottic suctioning ETTs in patients expected to be mechanically ventilated for >72 hours Armstrong Institute for Patient Safety and Quality 6

Structural measures: Quarterly evaluation 1.Use a closed ETT suctioning system 2.Change close suctioning catheters only as needed 3.Change ventilator circuits only if damaged or soiled 4.Change HME every 5-7 days and as clinically indicated 5.Provide easy access to NIVV equipment and institute protocols to promote use 6.Periodically remove condensate from circuits, keeping the circuit closed during the removal, taking precautions not to allow condensate to drain toward patient Armstrong Institute for Patient Safety and Quality 7 ETT endotrachael tube; HME heat moist exchanger; NIVV non-invasive ventilation

Structural measures: Quarterly evaluation 7.Use early mobility protocol 8.Perform hand hygiene 9.Avoid supine position 10.Use standard precautions while suctioning respiratory tract secretions 11.Use orotracheal intubation instead of nasotracheal 12.Avoid use of prophylactic systemic antimicrobials 13.Avoid non-essential tracheal suctioning 14.Avoid gastric over-distention Armstrong Institute for Patient Safety and Quality 8

Chlorhexidine when performing oral care

Chlorhexidine when performing oral care: VAP Prevention Guidelines No recommendation can be made for the routine use of an oral chlorhexidine rinse. (Unresolved issue) CDC; MMWR Recomm Rep. 2004;53:1-36 Recommends regular oral care. CHG effective in specific populations (ie: CABG); routine use is not recommended until more data is available. ATS/IDSA; AJRCCM 2005;171(4): Armstrong Institute for Patient Safety and Quality 10

Chlorhexidine when performing oral care: VAP Prevention Guidelines Oral antiseptic CHG should be considered. Based on 1 level 1 and 2 level 2 trials, use of oral antiseptic CHG may decrease VAP. Safety, feasibility, and cost considerations are all very favorable. Canadian VAP Prevention Guidelines; J Crit Care 2008;23(1): Perform regular oral care with an antiseptic solution. While the use of CHG is not specifically addressed, the 3 studies cited by the guideline all focused on cardiovascular surgery and demonstrated the efficacy of CHG. SHEA; ICHE 2008;29:S31-S40. Armstrong Institute for Patient Safety and Quality 11

CHG Oral Care: Evidence Gingival and dental plaque rapidly becomes colonized with bacteria in intubated patients due to poor oral hygiene and lack of mechanical elimination Meticulous oral care reduces microbial burden in upper airway Safety and feasibility of CHG oral care are favorable DeRiso A. Chest. 1996;109:1556. Chan E. BMJ. 2007;10:1136. Chlebicki M Crit Care Med 2007;35:595.

Topical CHG: 2007 Systematic Review and Meta-Analysis 7 RCTs evaluating CHG (1650 patients) Overall 26-30% VAP reduction –Fixed effects RR 0.74, 95%CI –Random effects RR 0.70, 95%CI Cardiac Surgery subgroup –59% VAP reduction –RR 0.41, 95% CI Armstrong Institute for Patient Safety and Quality 13 Chlebicki MP. Crit Care Med 2007;35:

Topical CHG: 2007 Systematic Review and Meta-Analysis Armstrong Institute for Patient Safety and Quality 14 Chlebicki MP. Crit Care Med 2007;35:

Oral Antiseptics: 2011 Systematic Review and Meta-Analysis 12 RCTs evaluating CHG (2341 patients) Overall 38% VAP reduction –RR 0.72, 95%CI Results varied by CHG concentration –2% > 0.2% > 0.12% Cardiac Surgery ICUs 59% VAP reduction –RR 0.41, 95% CI Armstrong Institute for Patient Safety and Quality 15 Labeau Lancet Infect Dis 2011;11:845-54

Oral Antiseptics: A Systematic Review and Meta-Analysis Armstrong Institute for Patient Safety and Quality 16 Labeau Lancet Infect Dis 2011;11:845-54

Oral Antiseptics: A Systematic Review and Meta-Analysis Variation by ICU Type Cardiac Surgery only (n=2, 914 patients) –RR 0.41, 95% CI Mixed ICUs (n=10, 1294 patients) –RR 0.77, 95% CI Surgery or Trauma (n=2, 273 patients) –RR 0.67, 95% CI Armstrong Institute for Patient Safety and Quality 17 Labeau Lancet Infect Dis 2011;11:845-54

CHG Oral Care: Recommendations Chorhexidine 0.12% oral solution (15 ml bid until 24 hours after extubation) for all intubated patients Exceptions Hypersensitivity to component of solution <18 years of age Brush patients’ teeth bid with soft toothbrush to remove dental plaque prior to using CHG Continue routine q4 hr routine oral care: cleaning and moistening mouth using oral swabs or sterile water and gauze

Subglottic suctioning ETTs in patients mechanically ventilated for >72 hours

Subglottic suctioning ETTs: VAP Prevention Guidelines Recommend ETTs with a dorsal lumen above the cuff to allow drainage (by continuous or frequent intermittent suctioning) of tracheal secretions. CDC; MMWR Recomm Rep. 2004;53:1-36 Recommend specially designed endotracheal tube (dorsal lumen) for continuous aspiration of subglottic secretions ATS/IDSA; AJRCCM 2005;171(4): Armstrong Institute for Patient Safety and Quality 20

Subglottic suctioning ETTs: VAP Prevention Guidelines Recommended subglottic secretion drainage in patients expected to be mechanically ventilated for more than 72 hours. Canadian VAP Prevention Guidelines; J Crit Care 2008;23(1): Recommend the use of cuffed ETT with in line or subglottic suctioning. SHEA; ICHE 2008;29:S31-S40. Armstrong Institute for Patient Safety and Quality 21

Subglottic suctioning ETTs: Evidence Drainage of subglottic secretions lessens the risk of aspiration Specially designed endotracheal tubes have been developed to provide continuous or intermittent subglottic secretion removal Kollef M. Chest. 1999;116:1339. Smulders K. Chest 2002;121:858.

Valles J, et al. Ann Intern Med. 1995;122:179. Subglottic Suctioning ETTs

Subglottic Suctioning ETTs: Evidence 13 RCTs evaluating subglottic secretion drainage (2442 patients) Overall 45% VAP reduction –RR 0.55 (95% CI 0.46–0.66) –NNT = day ICU LOS reduction 1.1 day duration of MV reduction Muscedere J. Crit Care Med. 2011;39:1985.

Subglottic Suctioning ETTs: A Systematic Review and Meta-Analysis Armstrong Institute for Patient Safety and Quality 25 Muscedere J. Crit Care Med. 2011;39:1985.

Subglottic Suctioning ETTs: A Systematic Review and Meta-Analysis Armstrong Institute for Patient Safety and Quality 26 Muscedere J. Crit Care Med. 2011;39:1985. Similar results if limited to studies of high methodologic quality Two studies evaluated only cardiac surgery patients (n=1057)

Subglottic Suctioning ETTs: A Cost Effectiveness Analysis Armstrong Institute for Patient Safety and Quality 27 Conclusion: Regular utilization of CSS-ETs may produce significant cost savings, irrespective of the increased costs of CSS-ETs.

Subglottic Suctioning ETTs: Recommendations Continuous subglottic suctioning system recommended for patients expected to be mechanically ventilated for >72 hours Unanswered questions –How to identify pts that will require MV > 3 days; most studies used SDD ETTs for all patients undergoing major surgery –Should ETTs be changed if patients require MV > 3 days.

Next Steps Discussion and agreement? Data Collection –Process measures –Opportunity to advance the science Timeline Armstrong Institute for Patient Safety and Quality 29